516 related articles for article (PubMed ID: 34348994)
21. Spontaneous in vitro senescence of glioma cells confirmed by an antibody against IDH1R132H.
Stoczynska-Fidelus E; Och W; Rieske P; Bienkowski M; Banaszczyk M; Winiecka-Klimek M; Zieba J; Janik K; Rosiak K; Treda C; Stawski R; Radomiak-Zaluska A; Piaskowski S
Anticancer Res; 2014 Jun; 34(6):2859-67. PubMed ID: 24922649
[TBL] [Abstract][Full Text] [Related]
22. Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas.
Nishikawa T; Watanabe R; Kitano Y; Yamamichi A; Motomura K; Ohka F; Aoki K; Hirano M; Kato A; Yamaguchi J; Maeda S; Kibe Y; Saito R; Wakabayashi T; Kato Y; Sato S; Ogino T; Natsume A; Ito I
Brain Tumor Pathol; 2022 Jan; 39(1):14-24. PubMed ID: 34826036
[TBL] [Abstract][Full Text] [Related]
23. IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.
Zhu H; Zhang Y; Chen J; Qiu J; Huang K; Wu M; Xia C
PLoS One; 2017; 12(1):e0169038. PubMed ID: 28052098
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice.
Kadiyala P; Carney SV; Gauss JC; Garcia-Fabiani MB; Haase S; Alghamri MS; Núñez FJ; Liu Y; Yu M; Taher A; Nunez FM; Li D; Edwards MB; Kleer CG; Appelman H; Sun Y; Zhao L; Moon JJ; Schwendeman A; Lowenstein PR; Castro MG
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33332283
[TBL] [Abstract][Full Text] [Related]
25. Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma.
Yang R; Zhao Y; Gu Y; Yang Y; Gao X; Yuan Y; Xiao L; Zhang J; Sun C; Yang H; Qin J; Li J; Zhang F; Zhang L; Ye J
Oncogene; 2020 Oct; 39(40):6340-6353. PubMed ID: 32855525
[TBL] [Abstract][Full Text] [Related]
26. Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.
Ohka F; Ito M; Ranjit M; Senga T; Motomura A; Motomura K; Saito K; Kato K; Kato Y; Wakabayashi T; Soga T; Natsume A
Tumour Biol; 2014 Jun; 35(6):5911-20. PubMed ID: 24590270
[TBL] [Abstract][Full Text] [Related]
27. An in vivo patient-derived model of endogenous IDH1-mutant glioma.
Luchman HA; Stechishin OD; Dang NH; Blough MD; Chesnelong C; Kelly JJ; Nguyen SA; Chan JA; Weljie AM; Cairncross JG; Weiss S
Neuro Oncol; 2012 Feb; 14(2):184-91. PubMed ID: 22166263
[TBL] [Abstract][Full Text] [Related]
28. An analysis of the prognostic value of IDH1 (isocitrate dehydrogenase 1) mutation in Polish glioma patients.
Lewandowska MA; Furtak J; Szylberg T; Roszkowski K; Windorbska W; Rytlewska J; Jóźwicki W
Mol Diagn Ther; 2014 Feb; 18(1):45-53. PubMed ID: 23934769
[TBL] [Abstract][Full Text] [Related]
29. Oncogenic MicroRNA-20a is downregulated by the HIF-1α/c-MYC pathway in IDH1 R132H-mutant glioma.
Xu Q; Ahmed AK; Zhu Y; Wang K; Lv S; Li Y; Jiang Y
Biochem Biophys Res Commun; 2018 May; 499(4):882-888. PubMed ID: 29625108
[TBL] [Abstract][Full Text] [Related]
30. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
31. IDH1(R132H) mutation causes a less aggressive phenotype and radiosensitizes human malignant glioma cells independent of the oxygenation status.
Kessler J; Güttler A; Wichmann H; Rot S; Kappler M; Bache M; Vordermark D
Radiother Oncol; 2015 Sep; 116(3):381-7. PubMed ID: 26328938
[TBL] [Abstract][Full Text] [Related]
32. A vaccine targeting mutant IDH1 induces antitumour immunity.
Schumacher T; Bunse L; Pusch S; Sahm F; Wiestler B; Quandt J; Menn O; Osswald M; Oezen I; Ott M; Keil M; Balß J; Rauschenbach K; Grabowska AK; Vogler I; Diekmann J; Trautwein N; Eichmüller SB; Okun J; Stevanović S; Riemer AB; Sahin U; Friese MA; Beckhove P; von Deimling A; Wick W; Platten M
Nature; 2014 Aug; 512(7514):324-7. PubMed ID: 25043048
[TBL] [Abstract][Full Text] [Related]
33. A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation.
Duncan CG; Barwick BG; Jin G; Rago C; Kapoor-Vazirani P; Powell DR; Chi JT; Bigner DD; Vertino PM; Yan H
Genome Res; 2012 Dec; 22(12):2339-55. PubMed ID: 22899282
[TBL] [Abstract][Full Text] [Related]
34. R132H IDH1 sensitizes glioma to the antiproliferative and cytotoxic effects of BET inhibition.
Sears TK; Woolard KD
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2275-2285. PubMed ID: 35467128
[TBL] [Abstract][Full Text] [Related]
35. IDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma.
Esmaeili M; Hamans BC; Navis AC; van Horssen R; Bathen TF; Gribbestad IS; Leenders WP; Heerschap A
Cancer Res; 2014 Sep; 74(17):4898-907. PubMed ID: 25005896
[TBL] [Abstract][Full Text] [Related]
36. Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance.
Ohba S; Mukherjee J; See WL; Pieper RO
Cancer Res; 2014 Sep; 74(17):4836-44. PubMed ID: 25035396
[TBL] [Abstract][Full Text] [Related]
37. Heterozygous IDH1
Wei S; Wang J; Oyinlade O; Ma D; Wang S; Kratz L; Lal B; Xu Q; Liu S; Shah SR; Zhang H; Li Y; Quiñones-Hinojosa A; Zhu H; Huang ZY; Cheng L; Qian J; Xia S
Oncogene; 2018 Sep; 37(38):5160-5174. PubMed ID: 29849122
[TBL] [Abstract][Full Text] [Related]
38. IDH1 mutation diminishes aggressive phenotype in glioma stem cells.
Yao Q; Cai G; Yu Q; Shen J; Gu Z; Chen J; Shi W; Shi J
Int J Oncol; 2018 Jan; 52(1):270-278. PubMed ID: 29115585
[TBL] [Abstract][Full Text] [Related]
39. Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma.
Chen YY; Ho HL; Lin SC; Hsu CY; Ho DM
Neurosurgery; 2019 Sep; 85(3):335-342. PubMed ID: 30113684
[TBL] [Abstract][Full Text] [Related]
40. The R132H mutation in IDH1 promotes the recruitment of NK cells through CX3CL1/CX3CR1 chemotaxis and is correlated with a better prognosis in gliomas.
Ren F; Zhao Q; Huang L; Zheng Y; Li L; He Q; Zhang C; Li F; Maimela NR; Sun Z; Jia Q; Ping Y; Zhang Z; Chen X; Yue Y; Liu S; Cao L; Zhang Y
Immunol Cell Biol; 2019 May; 97(5):457-469. PubMed ID: 30575118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]